Notice: This company has been marked as potentially delisted and may not be actively trading. Cerevel Therapeutics (CERE) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period AbbVie Tumbles After New Schizophrenia Drug Fails Two TrialsNovember 11, 2024 | finance.yahoo.comAbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock SurgesNovember 11, 2024 | benzinga.comAbbVie's closely watched schizophrenia drug fails two studies, shares slideNovember 11, 2024 | msn.comRapport Therapeutics adds new members to Board of DirectorsNovember 8, 2024 | markets.businessinsider.comAbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and ...November 1, 2024 | finance.yahoo.comAbbVie Inc. (NYSE:ABBV) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comAbbVie (ABBV) Q3 2024 Earnings Call TranscriptOctober 30, 2024 | msn.comAbbVie to buy Alzheimer's therapy developer Aliada for US$1.4 billionOctober 28, 2024 | msn.comAbbVie lowers first-quarter guidance after closing acquisition ImmunoGenOctober 14, 2024 | msn.comMindfulness Meditation Similar to Antidepressant for Reducing Anxiety SymptomsOctober 11, 2024 | msn.comAbbVie: A Strong Investment Opportunity In Neurological And Oncology BreakthroughsOctober 3, 2024 | seekingalpha.comAbbVie's Emraclidine: M4 Agonist Might Become Best-In-Class In SchizophreniaOctober 3, 2024 | seekingalpha.comKailera Therapeutics nets $400 million as weight-loss drug market heats upOctober 2, 2024 | msn.comAbbVie Inc. (ABBV) Projects Mid-Single-Digit Sales Growth Over Next 3 YearsSeptember 30, 2024 | msn.comHalf Year 2024 Ceres Power Holdings PLC Earnings Presentation TranscriptSeptember 30, 2024 | gurufocus.com8 Best Inexpensive Stocks To Invest In NowSeptember 27, 2024 | insidermonkey.com15 Unhealthiest Countries in Latin AmericaSeptember 27, 2024 | msn.comBristol Myers Gets US Nod for First New Schizophrenia Drug Type in DecadesSeptember 27, 2024 | msn.comBristol Myers wins US FDA approval for new type of schizophrenia drugSeptember 27, 2024 | msn.comAbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trialSeptember 27, 2024 | finance.yahoo.comAbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early DiseaseSeptember 27, 2024 | benzinga.comCardurion Pharmaceuticals Appoints Ron Renaud to Board of DirectorsSeptember 26, 2024 | finance.yahoo.comAbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's StudySeptember 26, 2024 | marketwatch.comBristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 YearsSeptember 20, 2024 | benzinga.comSchizophrenia: the new drug set to tackle the ‘cancer of psychiatry’September 19, 2024 | ft.comAbbVie (NYSE:ABBV) Expands Eye Care Portfolio with Ripple Therapeutics Collaboration, Boosts Growth PotentialSeptember 18, 2024 | finance.yahoo.com3 High-Dividend Pharma Blue Chips That Are on Sale Right NowSeptember 17, 2024 | stocknews.comQ4 2024 Ceres Global Ag Corp Earnings Call TranscriptSeptember 16, 2024 | gurufocus.comCeres Global Ag Corp (CERGF) Q4 2024 Earnings Call Transcript Highlights: Record Soybean Crush ...September 16, 2024 | gurufocus.comEli Lilly and AbbVie: J.P. Morgan Selects the Top Large-Cap Pharma Stocks to BuySeptember 16, 2024 | msn.comBain closes $3B biotech fund amid flurry of startup buyoutsSeptember 10, 2024 | finance.yahoo.comDelveInsight Business Research, LLP: Global Wireless Brain Sensors Market to Accelerate Substantially at a CAGR of ~9% by 2030 | DelveInsightAugust 27, 2024 | finanznachrichten.deAnalyst revises AbbieVie stock price target on drug-sale estimatesAugust 14, 2024 | msn.comABBV Sep 2024 200.000 callAugust 6, 2024 | ca.finance.yahoo.comCalifornia State Teachers Retirement System Acquires 47,747 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)California State Teachers Retirement System increased its holdings in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 63.9% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 122,437 shareAugust 5, 2024 | marketbeat.comABBV Aug 2024 245.000 callAugust 5, 2024 | ca.finance.yahoo.comABBV Aug 2024 187.500 putAugust 4, 2024 | uk.finance.yahoo.comPrice T Rowe Associates Inc. MD Cuts Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Price T Rowe Associates Inc. MD trimmed its holdings in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 53.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 335,357 shares of the biotechnology company's stock after selling 385,6August 4, 2024 | marketbeat.comABBV Aug 2024 160.000 callAugust 3, 2024 | uk.finance.yahoo.comAbbVie Completes Acquisition Of Cerevel; Reaffirms Full-year Adj. EPS Guidance RangeAugust 1, 2024 | markets.businessinsider.comAbbVie Completes Acquisition of Cerevel TherapeuticsAugust 1, 2024 | prnewswire.comCerevel Therapeutics Holdings Inc (673.MU)August 1, 2024 | finance.yahoo.comCerevel Therapeutics Target of Unusually Large Options Trading (NASDAQ:CERE)Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 15,827 call options on the company. This is an increase of approximately 633% compared to the typical volume of 2,158 call options.July 31, 2024 | marketbeat.comCerevel Therapeutics (NASDAQ:CERE) Reaches New 52-Week High at $44.66Cerevel Therapeutics (NASDAQ:CERE) Hits New 12-Month High at $44.66July 30, 2024 | marketbeat.comVanguard Group Inc. Purchases 88,941 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Vanguard Group Inc. lifted its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 1.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,463,911 shares of the biotechnolJuly 30, 2024 | marketbeat.comGabelli Funds LLC Has $27.22 Million Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Gabelli Funds LLC boosted its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 38.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 643,859 shares of the biotechnology company's stock after buying an additiJuly 27, 2024 | marketbeat.comCapital International Investors Lowers Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)Capital International Investors cut its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE - Free Report) by 70.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 253,495 shares of the biotechnology compJuly 26, 2024 | marketbeat.comIMGN Dec 2025 10.000 putJuly 26, 2024 | ca.finance.yahoo.comAfter FTC involvement, here’s when AbbVie-Cerevel deal could closeJuly 26, 2024 | bizjournals.comCheck Out What Whales Are Doing With CEREJuly 25, 2024 | benzinga.com Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address 2024's Must-Watch Stocks! (Ad)Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time. [Unlock Your Report Now] CERE Media Mentions By Week CERE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CERE News Sentiment▼0.000.56▲Average Medical News Sentiment CERE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CERE Articles This Week▼34▲CERE Articles Average Week Get Cerevel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CNX Resources News Today Warrior Met Coal News Today Arch Resources News Today Hallador Energy News Today Teva Pharmaceutical Industries News Today BeiGene News Today United Therapeutics News Today Viatris News Today Royalty Pharma News Today Summit Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CERE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerevel Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerevel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
